| Biomarker ID | 969 |
| PMID | 22887127 |
| Year | 2012 |
| Biomarker | hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | LowRisk(LR) Vs Metastatic CRPC |
| Type of Biomarker | Prognostic |
| Cohort | 28 patients with Localized low risk, 30 with Localized high risk, and 26 with Metastatic Castration Resistant Prostate Cancer were selected for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent dataset |
| Technical Name | hsa-miR-375, hsa-miR-96, hsa-miR-892b, hsa-miR-378, hsa-miR-302b, hsa-miR-548c-3p, hsa-miR-124, hsa-miR-141, hsa-miR-875-5p, hsa-miR-409-3p, hsa-miR-548a-3p, hsa-miR-623, hsa-miR-520d-5p, hsa-miR-489 |